文献速递妇科

使用自体腹直肌筋膜的骶骨阴道固定术:长期结局与并发症的队列研究

Sacrocolpopexy using autologous rectus fascia: Cohort study of long-term outcomes and complications.
PubMed 文献 · BJOG · 2022-02-16

本研究为单中心双向性队列研究,纳入2010年1月至2019年12月期间接受自体腹直肌筋膜腹部骶骨阴道固定术的132名女性,中位随访2.2年。复合失败率在12个月、2年、3年、5年分别为0.8%、3.5%、13.2%、28.3%。作者认为该术式对于希望避免合成网片的患者可考虑为安全有效的替代方案。

要点

  • 复合失败率5年达28.3%(95%CI 17.0%-44.8%),解剖失败率5年为6.8%。
  • 症状性失败率5年为13.1%,再治疗率5年为13.0%。
  • 作者认为自体腹直肌筋膜骶骨阴道固定术可考虑为避免合成网片的安全有效替代方案。

核心结论

  • 作者认为,自体腹直肌筋膜骶骨阴道固定术对于希望避免合成网片的患者可考虑为一种安全有效的替代方案。

研究设计与样本

  • 双向性队列研究,包含回顾性和前瞻性数据,在单一学术医疗中心进行。
  • 纳入2010年1月至2019年12月期间接受自体腹直肌筋膜腹部骶骨阴道固定术的女性,共132例。
  • 患者被招募进行随访,包括完成盆底困扰量表(PFDI-20)和盆腔器官脱垂定量(POP-Q)检查,并收集人口学和临床特征。

主要发现

  • 中位随访时间为2.2年。
  • 复合失败率在12个月为0.8%(95%CI 0.1%-5.9%),2年为3.5%(95%CI 1.1%-10.7%),3年为13.2%(95%CI 7.0%-24.3%),5年为28.3%(95%CI 17.0%-44.8%)。
  • 解剖失败率在12个月为0%,2年为1.4%(95%CI 0.2%-9.2%),3年为3.1%(95%CI 0.8%-12.0%),5年为6.8%(95%CI 2.0%-22.0%)。
  • 症状性失败率在12个月为0%,2年为1.3%(95%CI 0.2%-9.0%),3年为2.9%(95%CI 0.7%-11.3%),5年为13.1%(95%CI 5.3%-30.3%)。
  • 再治疗率在12个月和2年均为0.8%(95%CI 0.1%-5.9%),3年为9.4%(95%CI 4.2%-20.3%),5年为13.0%(95%CI 6.0%-27.2%)。

临床怎么用

  • 作者结论指出,对于希望避免合成网片的患者,自体腹直肌筋膜骶骨阴道固定术可考虑为安全有效的替代方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate objective and subjective outcomes of patients who underwent sacrocolpopexy using autologous rectus fascia to provide more data regarding non-mesh alternatives in pelvic organ prolapse surgery. DESIGN: Ambispective cohort study with retrospective and prospective data. SETTING: A single academic medical centre. POPULATION: Women who underwent abdominal sacrocolpopexy using autologous rectus fascia between January 2010 and December 2019. METHODS: Patients were recruited for a follow-up visit, including completing the Pelvic Floor Distress Inventory (PFDI-20) and Pelvic Organ Prolapse Quantification (POP-Q) examination. Demographic and clinical characteristics were collected. MAIN OUTCOME MEASURES: Composite failure, anatomic failure, symptomatic failure and retreatment. RESULTS: During the study period, 132 women underwent sacrocolpopexy using autologous rectus fascia. The median follow-up time was 2.2 years. Survival analysis showed that composite failure was 0.8% (95% CI 0.1%-5.9%) at 12 months, 3.5% (95% CI 1.1%-10.7%) at 2 years, 13.2% (95% CI 7.0%-24.3%) at 3 years and 28.3% (95% CI 17.0%-44.8%) at 5 years. The anatomic failure rate was 0% at 12 months, 1.4% (95% CI 0.2%-9.2%) at 2 years, 3.1% (95% CI 0.8%-12.0%) at 3 years and 6.8% (95% CI 2.0%-22.0%) at 5 years. The symptomatic failure rate was 0% at 12 months, 1.3% (95% CI 0.2%-9.0%) at 2 years, 2.9% (95% CI 0.7%-11.3%) at 3 years and 13.1% (95% CI 5.3%-30.3%) at 5 years. The retreatment rate was 0.8% (95% CI 0.1%-5.9%) at 12 months and 2 years, 9.4% (95% CI 4.2%-20.3%) at 3 years and 13.0% (95% CI 6.0%-27.2%) at 5 years. CONCLUSION: Autologous rectus fascia sacrocolpopexy may be considered a safe and effective alternative for patients who wish to avoid synthetic mesh. TWEETABLE ABSTRACT: Sacrocolpopexy using autologous rectus fascia is a safe and effective alternative to synthetic mesh.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Wang R, Reagan K, Boyd S, et al. Sacrocolpopexy using autologous rectus fascia: Cohort study of long-term outcomes and complications. BJOG. 2022. PMID: 35104383. doi:10.1111/1471-0528.17107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。